Parker-Hannifin weakness overdone, says MKM Partners MKM Partners expects Parker-Hannifin's orders to rebound in its March quarter. The firm views investors' concerns about the company's December quarter results as overdone, and it keeps a $130 price target and Buy rating on the stock.
News For PH From The Last 14 Days
Check below for free stories on PH the last two weeks.
Parker-Hannifin partners with Cleveland clinic for medical solutions Parker Hannifin is developing more than 100 potential medical advancements with Cleveland Clinic, the nonprofit academic medical center that integrates clinical care with research and education. Several of the medical solutions have been submitted for regulatory approval in Europe and the U.S., and are anticipated to be ready for commercial launch as early as 2015.